Searched for
NICHI IKO
Kedaara, TA Associates vie for minority stake in Sagent PharmaKedaara Capital and TA Associates are in talks to acquire a significant minority stake in Sagent Pharma, valued at $500-600 million. Invest...- Nikkei ends lower on auto export slump, geopolitical tensionsThe Nikkei had posted its biggest intraday percentage gain in three months in the previous session.
- Exploring ways to establish presence in China as part of APAC region push: LupinThe Mumbai-based firm expects to generate revenues of over USD 100 million from the region, excluding the Japanese market, over the next fe...
- Lupin aims to be numero uno in biosimilar etanercept in JapanIt takes 12-13 months for the Japanese drug authorities to give product approvals.
- Lupin, Nichi-Iko tie up for commercialization of biosimilar Etanercept in JapanMumbai based Lupin pharma and Japan's Nichi-Iko have tied up for the distribution, promotion and sale of Lupin’s recently-filed biosimilar ...
- Lupin in talks with Japan's Astellas, Shionogi to buy their off-patent drug brandsThe acquisition will result in a wider offering for Lupin in Japanese market where its sales last fiscal stood at Rs 1,364 crore.
- Sun Pharma’s Novartis deal could be a bright spotSun Pharma’s acquisition of 14 established prescription brands of Swiss drug maker Novartis in Japan will give it a headstart in the $73 bi...
- Indian drug companies like Glenmark, Dr Reddy's, Sun Pharma break into world’s fastest growing listThe club of the fastest growing generic companies in the world is dominated by US companies , led by US-based Sagent Pharma, which witnesse...
Load More